Study Evaluating SKI-606 Administered to Healthy Subjects

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: November 29, 2006
Last updated: December 3, 2007
Last verified: December 2007

Safety and tolerability of SKI-606 in healthy subjects; the influence of food intake on the same.

Condition Intervention Phase
Drug: SKI-606
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Pharmacokinetics; safety and tolerability; influence of food.

Study Start Date: November 2006
Study Completion Date: August 2007

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy
  Contacts and Locations
Please refer to this study by its identifier: NCT00406406

Utrecht, Netherlands, 3584 CJ
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Netherlands,
  More Information

No publications provided Identifier: NCT00406406     History of Changes
Other Study ID Numbers: 3160A1-103
Study First Received: November 29, 2006
Last Updated: December 3, 2007
Health Authority: Netherlands: Medical Ethics Review Committee (METC) processed this record on April 16, 2014